Efficacy and Safety Study of Narsoplimab in Pediatric Patients With High-Risk Hematopoietic Stem Cell Transplant TMA
Status:
Recruiting
Trial end date:
2025-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and efficacy of narsoplimab in pediatric
patients with thrombotic microangiopathies (TMA) following hematopoietic stem cell transplant
(HSCT).